优化使用人口药物动力学模型在重症患者中使用费诺巴比特的剂量,这些患者具有耐火和超耐火状态的
Maximilian Stoschus1,2, Moritz L Schmidbauer1, Johannes Starp2
1Department of Neurology, Ludwig Maximilian University (LMU) Hospital, LMU Munich, Munich, Germany.
Epilepsia
|June 26, 2025
概括
目前以体重为基础的剂量对耐火状态 (RSE) 和超耐火状态 (SRSE) 无效. 这项研究揭示了高的药理动力学变异性,导致非最佳的巴比塔尔剂量和低的目标在重症患者的实现.
科学领域:
- 在重症监护医学的药理动力学和药理动力学.
- 耐火性的神经临床护理和管理.
- 治疗药物监测和精确剂量策略.
背景情况:
- 基于体重的巴比他标准剂量不足以解决耐火性和超耐火性状态 (RSE,SRSE) 的药理学变异性.
- 危急病患者表现出显著的器官功能障碍,影响药物处置,并需要个性化剂量以提高安全性和有效性.
- 了解巴丁的药理动力学对于优化RSE和SRSE治疗至关重要.
研究的目的:
- 在RSE和SRSE患者中量化费诺巴比他的主要药理动力学变异性.
- 在这个患者群体中开发出巴比他的人口药理动力学模型.
- 为了实现个性化的剂量策略,以改善治疗结果.
主要方法:
- 追溯分析治疗药物监测 (TDM) 样本来自神经重症监护病房的37名RSE/SRSE患者.
- 使用非线性混合效应建模 (NONMEM/MONOLIX) 开发一个群体药理动力学模型.
- 模拟最佳剂量方案和计算值度 (18-40 mg/L) 的目标达到.
主要成果:
- 费诺巴比塔尔呈现出高口服生物利用率 (96%),分布量 (V) 和清除量 (CL),与非重症监护数据一致.
- 理想体重 (IBW) 是唯一显著的共同变量,与费诺巴比他剂量要求有正相关.
- 高的个体间 (81.36% CV on V,41.36% CV on CL) 和间接变异性 (36.85% CV on CL) 导致~40%的目标实现.
结论:
- 开发的药理动力学模型描述了RSE/SRSE中的巴比特的处置,突出了IBW的影响.
- 在重症监护患者中,显著的药物动力学变化导致药物暴露低于最佳水平,目标达到较低.
- 基于模型的精确剂量对改善RSE和SRSE的巴比塔尔目标达到具有前景.
相关概念视频
Pharmacokinetic Models: Comparison and Selection Criterion
153
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
153
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
309
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
309
Analysis of Population Pharmacokinetic Data
396
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
396
Pharmacokinetic Models: Overview
1.2K
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
1.2K
One-Compartment Open Model for IV Bolus Administration: General Considerations
324
The one-compartment model is a pharmacokinetic tool that models the body as a single, uniform compartment, facilitating the understanding of drug distribution and elimination. This model is particularly beneficial for intravenous (IV) bolus administration, where the drug rapidly circulates throughout the body.
The drug's presence in the body is defined by an equation representing the difference between the rates of drug entry and exit. Key parameters—elimination rate constant,...
The drug's presence in the body is defined by an equation representing the difference between the rates of drug entry and exit. Key parameters—elimination rate constant,...
324
Nonlinear Pharmacokinetics: Overview
569
Nonlinear or dose-dependent pharmacokinetics is a phenomenon that occurs when the pharmacokinetic parameters of certain drugs deviate from linear pharmacokinetics at higher doses. These drugs do not follow the expected first-order kinetics, where the rate of drug elimination is directly proportional to the drug concentration. Instead, they exhibit a nonlinear relationship, which can be attributed to several factors.
Nonlinearity can arise due to the saturation of plasma protein-binding or...
Nonlinearity can arise due to the saturation of plasma protein-binding or...
569


